Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05520775 · ClinicalTrials.gov registry record · Phase 2
Semaglutide for Alcohol Use Disorder
A Phase 2 study of Alcohol Use Disorder and Cigarette Smoking, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT05520775 is a Phase 2 study of Alcohol Use Disorder and Cigarette Smoking that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 48 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05520775, a Phase 2 study of Alcohol Use Disorder and Cigarette Smoking, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an early-Phase II human laboratory trial using a randomized, placebo-controlled, dose-ranging design to investigate the effects of semaglutide, a GLP-1 receptor agonist, on alcohol-related outcomes in adults with alcohol use disorder (AUD).
Conditions Studied
Interventions
- DRUG Semaglutide
- DRUG Sham/placebo
Study Locations (1)
North Carolina
- UNC-Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2022-09-02 |
| Est. Completion | 2024-04-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05520775
The ClinicalTrials.gov registry entry for NCT05520775 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (85% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Semaglutide is the first listed.
NCT05520775 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05520775 about?
NCT05520775 is a clinical study titled "Semaglutide for Alcohol Use Disorder". This is an early-Phase II human laboratory trial using a randomized, placebo-controlled, dose-ranging design to investigate the effects of semaglutide, a GLP-1 receptor agonist, on alcohol-related outcomes in adults with alcohol use disorder (AUD).
What is the current status of trial NCT05520775?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2022-09-02. Estimated completion is 2024-04-19.
What conditions does trial NCT05520775 study?
This clinical trial studies the following conditions: Alcohol Use Disorder, Cigarette Smoking.
What interventions are being tested in trial NCT05520775?
The interventions under investigation include: Semaglutide (DRUG), Sham/placebo (DRUG).
Who is sponsoring clinical trial NCT05520775?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05520775 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking
RECRUITING · Phase 2
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial
RECRUITING · Phase 2
-
Cannabis' Impact on Alcohol Consumption
RECRUITING · Phase 2
-
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
RECRUITING · Phase 2
-
Semaglutide Therapy for Alcohol Reduction (STAR)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.